



Suppl. Figure 1




Suppl. Figure 1. Knockdown of RIPK1 significantly increases the serum levels of cytokines/chemokines (**A**) and hepatic leukocytes (**B**) in response to αGalCer treatment. Groups of mice were pretreated with Cont ASO or RIPK1 ASO to silence RIPK1 prior to αGalCer (4μg/mouse, i.p.). (**A**) Serum cytokine/chemokine levels at 6hr after αGalCer (n=4-6). *p<0.05 vs. Cont ASO; (**B**) Total numbers of hepatic leukocytes per liver tissue at 6hr after αGalCer. *p<0.05 vs. Cont ASO. **Reduced NKT numbers in both groups reflected an activation-induced cell death of NKT cells in response to αGalCer as expected.

Suppl. Figure 2




Suppl. Figure 2. RIPK1 knockdown does not sensitize to Fas-mediated liver injury. Groups of Cont ASO and RIPK1 ASO pretreated mice (n=5 per group) were administered i.p with anti-Fas (Jo2, 4 μ g per mouse). **(A)** Serum ALT at 6 and 24hr after Jo2; **(B)** H&E staining of liver sections at 24hr after Jo2.

Suppl. Figure 3



Suppl. Figure 3. Knockdown of RIPK1 does not impair the induction of NF-κB downstream genes. **(A)** qPCR analysis of mRNA levels of c-FLIP and cIAP1 in the liver from Cont ASO and RIPK1 ASO treated mice at indicated times after αGalCer treatment. **(B)** mRNA levels in the liver tissues from Cont ASO and RIPK1 ASO treated mice at 3hr after αGalCer treatment were analyzed by mouse NF-κB Signaling Pathway RT² ProfilerTM PCR array kit (QIAGEN). Fold changes at 3hr over time zero were expressed. **(C)** mRNA levels in the primary hepatocytes isolated from Cont ASO and RIPK1 ASO treated mice at 3hr after αGalCer treatment were analyzed by mouse NF-κB Signaling Pathway RT² ProfilerTM PCR array kit (QIAGEN). Fold changes at 3hr over time zero were expressed.

Suppl. Figure 4



Suppl. Figure 4. Necostatin-1 (Nec-1) does not prevent α GalCer-mediated liver injury. Groups of mice were pretreated with inactive Nec-1 or Nec-1 (1.65 mg/kg, i.p.) 15min prior to α GalCer (4 μ g per mouse, i.p.). **(A)** Serum ALT at 24hr after α GalCer (n=5 per group), $p>0.05$; **(B)** H&E staining of liver sections at 24hr after α GalCer.